• Abstract
• Full-Text PDF [370 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Stöllberger, C
• Finsterer, J
• [+] on Google Scholar
• Stöllberger, C
• Finsterer, J
• [+] on PubMed
• Stöllberger, C
• Finsterer, J

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Pharmaceuticals 2012, 5(2), 155-168; doi:10.3390/ph5020155

Review

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Claudia Stöllberger ^1,*  and Josef Finsterer ^1,2

¹ Krankenanstalt Rudolfstiftung, Second Medical Department, Juchgasse 25, Wien A-1030, Austria ² Danube University Krems, Doktor-Karl-Dorrek-Straße 30, Krems A-3500, Austria

* Author to whom correspondence should be addressed.

Received: 26 December 2011; in revised form: 1 February 2012 / Accepted: 1 February 2012 / Published: 3 February 2012

(This article belongs to the Special Issue Anticoagulants)

Download PDF Full-Text [370 KB, uploaded 3 February 2012 09:46 CET]

Abstract: Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are still unclear, like laboratory monitoring, use in elderly patients, drug- and food-interactions and use in patients with renal insufficiency. Additionally, there is no antidote for dabigatran. Thus, aim of the present review is to give an overview of concerns and unresolved issues concerning dabigatran.

Keywords: atrial fibrillation; dabigatran; anticoagulation

Article Statistics

Cite This Article